<DOC>
	<DOCNO>NCT01476956</DOCNO>
	<brief_summary>Recruited patient include begin Disease-Modifying Antirheumatic Drug ) DMARD therapy change DMARD therapy . Disease activity monitor systematically every 3 month Disease Activity Score . Changes standard DMARD and/or anti-Tumor Necrosis Factor α ( anti-TNFα ) therapy make accord specific recommendation patient receive therapy . Biomarker sample collect every 3 month prior change DMARD and/or anti-TNF therapy define . A blood sample ( 40 ml ) serum take biomarker study process accord international committee Outcome Measures Rheumatology ( OMERACT ) recommendation minimal handle biomarker sample . A urine sample ( 20 ml ) also take processed serum . Radiography ( X-rays ) conduct every 6 month ( baseline , 6 , 12 , 18 , 24 month ) . Patients follow 2 year .</brief_summary>
	<brief_title>Assess Structural Damage Rheumatoid Arthritis Using Biomarkers Radiography</brief_title>
	<detailed_description>Treatment Disease Activity Score ( DAS ) driven . Changes standard DMARD and/or anti-TNFα therapy implement accord 2010 European League Rheumatism ( EULAR ) recommendation state target remission ( DAS44 &lt; 1.6 ) patient receive standard DMARD therapy set early disease target low disease activity state ( LDAS ) ( DAS44 ≤2.4 ) patient receive anti-TNFα therapy set establish disease .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion Criteria ( select ) : 18 year age old RA accord 2010 Rheumatoid Arthritis Classification Criteria Joint symptom ≥ 3 month prior screen DAS44 &gt; 2.4 About start DMARD therapy ( methotrexate , salazopyrin , hydroxychloroquine , chloroquine , leflunomide ) increase dose methotrexate ≥10 mg weekly maximum dose 25mg weekly ( already receive &gt; 15mg require addon DMARD/antiTNF switch alternative DMARD ) , addon alternative DMARD , switch alternative DMARD , start first antiTNFα agent ( adalimumab , etanercept , infliximab , certolizumab pegol , golimumab ) If already DMARD therapy stable 3 month prior baseline visit If already systemic steroid , dose must stable ( prednisone ≤ 7.5mg/day ) 1 month prior baseline visit Patient available follow minimum 24 month baseline visit Exclusion Criteria ( select ) : Intraarticular steroid injection within 4 week prior baseline visit Prior treatment antiTNFα biological agent ( rituximab , abatacept , tocilizumab ) Malignancy within past 5 year ( basal cell carcinoma adequately treat excised , squamous cell cancer skin , cervical carcinoma situ ) History : Serious infection ( define require parenteral antibiotic hospitalization ) within 3 month prior baseline visit ; Active tuberculosis history tuberculosis without documented curative treatment and/or positive tuberculin reaction PPD ( Purified Protein Derivative ) For patient start antiTNF therapy , positive TB screen test record effective prophylaxis accord local expert recommendation Known infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B Hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>